Editing Selective estrogen receptor modulator (section)

{{Short description|Drugs acting on the estrogen receptor}}
{{Infobox drug class
| Image = Tamoxifen2DACS.svg
| ImageClass = skin-invert-image
| Alt =
| Caption = [[Tamoxifen]], a [[nonsteroidal]] [[triphenylethylene]] antiestrogen and a widely used drug in the treatment of [[breast cancer]].
| Width = 250px
| Synonyms = SERM; Estrogen receptor agonist/antagonist; ERAA
<!-- Class identifiers -->
| Use = [[Breast cancer]], [[infertility]], [[osteoporosis]], [[vaginal atrophy]], [[dyspareunia]], [[hormonal contraceptive|contraception]], [[male hypogonadism]], [[gynecomastia]], [[breast pain]], others
| ATC_prefix = G03XC
| Biological_target = [[Estrogen receptor]]
| Chemical_class =
<!-- Clinical data -->
| Drugs.com =
| Consumer_Reports =
| medicinenet =
| rxlist =
<!-- External links -->
| MeshID =
}}

'''Selective estrogen receptor modulators''' ('''SERMs'''), also known as '''estrogen receptor agonists/antagonists''' ('''ERAAs'''),<ref name="pmid28628428">{{cite journal | vauthors = Hirsch HD, Shih E, Thacker HL | title = ERAAs for menopause treatment: Welcome the 'designer estrogens' | journal = Cleve Clin J Med | volume = 84 | issue = 6 | pages = 463–470 | date = June 2017 | pmid = 28628428 | doi = 10.3949/ccjm.84a.15140 | doi-access = free }}</ref><ref name="pmid32576803">{{cite journal | vauthors = Archer DF | title = Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy | journal = Menopause | volume = 27 | issue = 8 | pages = 846–847 | date = August 2020 | pmid = 32576803 | doi = 10.1097/GME.0000000000001600 | s2cid = 220045301 }}</ref> are a class of [[drug]]s that act on [[estrogen receptor]]s (ERs).<ref name="Riggs_2003">{{cite journal | vauthors = Riggs BL, Hartmann LC | title = Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice | journal = The New England Journal of Medicine | volume = 348 | issue = 7 | pages = 618–29 | date = Feb 2003 | pmid = 12584371 | doi = 10.1056/NEJMra022219 }}</ref> Compared to pure ER [[agonist]]s–[[Receptor antagonist|antagonists]] (e.g., [[full agonist]]s and [[silent antagonist]]s), SERMs are more tissue-specific, allowing them to selectively inhibit or stimulate [[estrogen]]-like action in various tissues.

{{TOC limit|3}}